Literature DB >> 15794721

Fluoroquinolones and tendon disorders.

Asa Melhus1.   

Abstract

Fluoroquinolones are the most potent oral antibiotics in clinical use today. Increasingly, these drugs are being prescribed for relatively benign infections and for new categories of patients, including paediatric patients. As their use becomes more frequent, so will the adverse events. This review focuses on a rare but debilitating adverse reaction, the fluoroquinolone-associated tendinopathy. Despite many published case reports and approximately 3500 cases reported to the World Health Organization Collaborating Centre for Drug Monitoring, little is known about the mechanisms behind this fluoroquinolone-specific toxicity. Data on chemical properties, mode of action, pharmacokinetic features, clinical presentation and risk factors in relation to tendon toxicity are discussed and the literature reviewed. As long as the musculoskeletal toxicity cannot be predicted by in vitro or in vivo models and this class of antibiotics is one of the most commonly linked to selection of resistant bacteria, a more prudent use of fluoroquinolones is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794721     DOI: 10.1517/14740338.4.2.299

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  14 in total

1.  Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study.

Authors:  Giovanni Corrao; Antonella Zambon; Lorenza Bertù; Anna Mauri; Valentina Paleari; Camillo Rossi; Mauro Venegoni
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  The ruptured Achilles tendon: a current overview from biology of rupture to treatment.

Authors:  G Thevendran; K M Sarraf; N K Patel; A Sadri; P Rosenfeld
Journal:  Musculoskelet Surg       Date:  2013-04-02

Review 3.  Safety Concerns Surrounding Quinolone Use in Children.

Authors:  Karisma Patel; Jennifer L Goldman
Journal:  J Clin Pharmacol       Date:  2016-03-28       Impact factor: 3.126

4.  Systemic antimicrobial therapy in osteomyelitis.

Authors:  Henry S Fraimow
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

Review 5.  Quinolones: review of psychiatric and neurological adverse reactions.

Authors:  Ana M Tomé; Augusto Filipe
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

6.  Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study.

Authors:  Jacob Sode; Niels Obel; Jesper Hallas; Annmarie Lassen
Journal:  Eur J Clin Pharmacol       Date:  2007-03-03       Impact factor: 2.953

Review 7.  Nonproliferative and Proliferative Lesions of the Rat and Mouse Skeletal Tissues (Bones, Joints, and Teeth).

Authors:  Stacey Fossey; John Vahle; Philip Long; Scott Schelling; Heinrich Ernst; Rogely Waite Boyce; Jacquelin Jolette; Brad Bolon; Alison Bendele; Matthias Rinke; Laura Healy; Wanda High; Daniel Robert Roth; Michael Boyle; Joel Leininger
Journal:  J Toxicol Pathol       Date:  2016-07-29       Impact factor: 1.628

Review 8.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

10.  Systemic use of fluoroquinolone in children.

Authors:  Soo-Han Choi; Eun Young Kim; Yae-Jean Kim
Journal:  Korean J Pediatr       Date:  2013-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.